Search Results
You are looking at 1 - 1 of 1 items for
- Author: David Buck x
- Refine by access: All content x
Search for other papers by Kreepa G Kooblall in
Google Scholar
PubMed
Search for other papers by Victoria J Stokes in
Google Scholar
PubMed
Search for other papers by Omair A Shariq in
Google Scholar
PubMed
Search for other papers by Katherine A English in
Google Scholar
PubMed
Search for other papers by Mark Stevenson in
Google Scholar
PubMed
Search for other papers by John Broxholme in
Google Scholar
PubMed
Search for other papers by Benjamin Wright in
Google Scholar
PubMed
Search for other papers by Helen E Lockstone in
Google Scholar
PubMed
Search for other papers by David Buck in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by Christopher J Yates in
Google Scholar
PubMed
Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, UK
Search for other papers by Rajesh V Thakker in
Google Scholar
PubMed
Search for other papers by Kate E Lines in
Google Scholar
PubMed
Multiple endocrine neoplasia type 1 (MEN1), caused by mutations in the MEN1 gene encoding menin, is an autosomal dominant disorder characterised by the combined occurrence of parathyroid, pituitary and pancreatic neuroendocrine tumours (NETs). Development of these tumours is associated with wide variations in their severity, order and ages (from <5 to >80 years), requiring life-long screening. To improve tumour surveillance and quality of life, better circulating biomarkers, particularly for pancreatic NETs that are associated with higher mortality, are required. We, therefore, examined the expression of circulating miRNA in the serum of MEN1 patients. Initial profiling analysis followed by qRT-PCR validation studies identified miR-3156-5p to be significantly downregulated (−1.3 to 5.8-fold, P < 0.05–0.0005) in nine MEN1 patients, compared to matched unaffected relatives. MEN1 knock-down experiments in BON-1 human pancreatic NET cells resulted in reduced MEN1 (49%, P < 0.05), menin (54%, P < 0.05) and miR-3156-5p expression (20%, P < 0.005), compared to control-treated cells, suggesting that miR-3156-5p downregulation is a consequence of loss of MEN1 expression. In silico analysis identified mortality factor 4-like 2 (MOR4FL2) as a potential target of miR-3156-5p, and in vitro functional studies in BON-1 cells transfected with either miR-3156-5p mimic or inhibitors showed that the miR-3156-5p mimic significantly reduced MORF4L2 protein expression (46%, P < 0.005), while miR-3156-5p inhibitor significantly increased MORF4L2 expression (1.5-fold, P < 0.05), compared to control-treated cells, thereby confirming that miR-3156-5p regulates MORF4L2 expression. Thus, the inverse relationship between miR-3156-5p and MORF4L2 expression represents a potential serum biomarker that could facilitate the detection of NET occurrence in MEN1 patients.
